Taiyo Otoshi

Dr. Taiyo Otoshi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2020 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
TOTaiyo Otoshi
Taiyo Otoshi
TYTakeshi Yamasaki
Takeshi Yamasaki
YHYukiyoshi Hirayama
Yukiyoshi Hirayama
JUJunji Uchida
Junji Uchida

6 June 2022 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
YIY Ishihama
Y Ishihama
KFKazuo Fukumoto
Kazuo Fukumoto
Ryu WatanabeRyu Watanabe
Ryu Watanabe
SNS Nakatani
S Nakatani
ATA Tsuda
A Tsuda
MHMotomu Hashimoto
Motomu Hashimoto
Immunoglobulin A (IgA) vasculitis (formerly known as Henoch–Schönlein purpura) is a small-vessel vasculitis with IgA-dominant immune deposits that typically involves the skin, gut, and glomeruli, a...

17 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Junji UchidaJunji Uchida
Junji Uchida
SNShunji Nishide
Shunji Nishide
YTYuji Takeyama
Yuji Takeyama
TOTaiyo Otoshi
Taiyo Otoshi
MKMinoru Kato
Minoru Kato
KKKatsuyuki Kuratsukuri
Katsuyuki Kuratsukuri
Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV out-comes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and evero-limus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of base-line. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated re-jection, or antibody-mediated rejection occurred; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.

13 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Junji UchidaJunji Uchida
Junji Uchida
SNShunji Nishide
Shunji Nishide
YTYuji Takeyama
Yuji Takeyama
TOTaiyo Otoshi
Taiyo Otoshi
MKMinoru Kato
Minoru Kato
KKKatsuyuki Kuratsukuri
Katsuyuki Kuratsukuri
Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV outcomes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and everolimus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of baseline. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated rejection, or antibody-mediated rejection occurred during letermovir prophylaxis; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.

26 October 2023 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SYShoma Yamamoto
Shoma Yamamoto
MKMinoru Kato
Minoru Kato
TMTaisuke Matsue
Taisuke Matsue
NYNao Yukimatsu
Nao Yukimatsu
YTYuji Takeyama
Yuji Takeyama
Junji UchidaJunji Uchida
Junji Uchida
New approaches involving immune checkpoint inhibitors and antibody-drug conjugates prolong overall survival in patients with metastatic urothelial carcinoma. However, the access to such systemic therapy in clinical practice is suboptimal, and whether these agents improve overall survival in patients with metastatic urothelial carcinoma over time remains unclear. Hence, we investigated the overall survival trend from the initiation of first-line therapy with these agents to identify changes due to the medication and time of treatment initiation. We retrospectively evaluated 195 patients from a single center. They were treated with chemotherapy, pembrolizumab, or avelumab or enfortumab vedotin. The treatment was categorized into chemotherapy, pembrolizumab or avelumab/enfortumab vedotin period. The new agents prolonged overall survival from the start of first-line therapy. Furthermore, sequential treatment with these agents in real-world clinical practice has been reported to prolong overall survival. These study results will have major implications when a new first-line therapy is approved in the future.